Forte Biosciences Inc.
(FBRX)
undefined
undefined%
At close: undefined
23.15
-1.59%
After-hours Dec 13, 2024, 04:00 PM EST
Company Description
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States.
It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata.
The company is headquartered in Dallas, Texas.
Forte Biosciences Inc.
Country | United States |
IPO Date | Apr 13, 2017 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 11 |
CEO | Dr. Paul A. Wagner Ph.D. |
Contact Details
Address: 3060 Pegasus Park Drive Dallas, Texas United States | |
Website | https://www.fortebiorx.com |
Stock Details
Ticker Symbol | FBRX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001419041 |
CUSIP Number | 34962G109 |
ISIN Number | US34962G1094 |
Employer ID | 26-1243872 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Paul A. Wagner Ph.D. | Chief Executive Officer, President & Chairman |
Antony A. Riley CPA | Chief Financial Officer |
Christopher Roenfeldt | Chief Operating Officer |
Dr. Barbara K. Finck M.D. | Chief Medical Clinician & Director |
Steven Ruhl | Chief Technical Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 13, 2024 | S-3 | Filing |
Dec 06, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Dec 03, 2024 | 8-K | Current Report |
Nov 22, 2024 | 4 | Filing |
Nov 20, 2024 | 8-K | Current Report |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 14, 2024 | 10-Q | Quarterly Report |
Nov 14, 2024 | 8-K | Current Report |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Oct 02, 2024 | 4 | Filing |